Ampersand Biomedicines Acquires Abcheck To Accelerate Platform And Product Development
Acquiring Company
Ampersand Biomedicines
Acquired Company
AbCheck s.r.o.
Boston
PlzenBiotechnologyBiotechnologyDescription
Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the acquisition of AbCheck s.r.o., a technology company with a suite of antibody discovery technologies for challenging targets and a wholly-owned subsidiary of Affimed GmbH. The addition of AbCheck’s broad discovery platform and deep expertise in antibody generation and optimization will enable cost-effective and strategic acceleration of Ampersand’s Address, Navigate, Determine (AND)TM Platform.
Quick answer
Ampersand Biomedicines is acquiring AbCheck s.r.o., announced January 3, 2024. Ampersand Biomedicines is based in Boston, Massachusetts, United States.
- Who acquired AbCheck s.r.o?
- Ampersand Biomedicines agreed to acquire AbCheck s.r.o. on January 3, 2024.
- How much did Ampersand Biomedicines pay for AbCheck s.r.o?
- The deal value was not disclosed.
- What does Ampersand Biomedicines do?
- Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else.
- Where are Ampersand Biomedicines and AbCheck s.r.o. based?
- Ampersand Biomedicines is based in Boston, Massachusetts, United States. AbCheck s.r.o. is based in Plzen, Czech Republic.
- Who are the decision-makers at Ampersand Biomedicines?
- Fundz holds 2 contacts at Ampersand Biomedicines. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (February 16, 2024)
- Petauri™ Acquires FORCE Communications (February 14, 2024)
- Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (February 6, 2024)
- Novo Holdings to Acquire Catalent (February 5, 2024)
- Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to March 3, 2024 (February 5, 2024)
- Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications (January 30, 2024)
Who to call at Ampersand Biomedicines, and when
When Ampersand Biomedicines changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ampersand Biomedicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ampersand Biomedicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ampersand Biomedicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ampersand Biomedicines makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired AbCheck s.r.o.?
AbCheck s.r.o. was acquired by Ampersand Biomedicines, based in Boston. The deal was reported on January 3, 2024. Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. Ampersand Biomedicines is privately held and operates in Biotechnology.
When did Ampersand Biomedicines acquire AbCheck s.r.o.?
Ampersand Biomedicines's acquisition of AbCheck s.r.o. was reported on January 3, 2024. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does AbCheck s.r.o. do?
AbCheck discovers and optimizes human therapeutic antibodies with one of the industry’s most versatile technology platforms. It is privately held, operating in Biotechnology, and is based in Plzen.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.